Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy

The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease.

* Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting? * Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Alzheimer Dementia Alzheimer Disease Brain Diseases Central Nervous System Diseases Cognitive Abnormality Confusion Delirium Confusional State Dementia Encephalopathy Mental Disorders Nervous System Diseases Neurobehavioral Manifestations Neurocognitive Disorders Neurodegenerative Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Tauopathies

Age range

60 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cumberland Medical Center, Crossville, Tennessee, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Ages 60 to 90 years old
No prior diagnosis of dementia
Currently hospitalized with cognitive diagnosis, including but no limited to; delirium, encephalopathy, etc. thought to be secondary to a toxic/metabolic state

Exclusion criteria

Age under 60 years
Prior diagnosis of dementing illness or other organic etiology to cognitive impairment

Treatment and study plan

Quest AD-Detect blood test

Diagnostic Test

Blood will be collected and sent for testing using the Quest AD-Detect blood test

Primary outcomes

To show the percentage of patients (21 patients in the study) who presented with a cognitive diagnosis (including but not limited to delirium, encephalopathy, etc.) that have a positive biomarker for Alzheimer's dementia

Time frame: From enrollment to 6 month follow up appointment with Neurology Clinic.

A Six month follow up with the Neurology clinic to discuss the results of Quest AD Detect (p-tau217), those patients who are found to have a positive outcome will receive additional follow-up in the Neurology clinic (which could include the use of additional lab tests or further diagnostic testing).

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Research Nurse Coordinator

CONTACT

[email protected]

865-331-1337

Sponsors and collaborators

Lead sponsor

Covenant Health, US

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Oct 29, 2025
Registry last updated: Oct 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting